LACHEN, SWITZERLAND

Octapharma to present new clinical and scientific data from across Octapharma’s haematology and critical care portfolios during the ISTH 2022 Congress Data to be presented in 11 poster presentations and during two Supported Symposia New data from the extensive clinical trial programme with Nuwiq® (simoctocog alfa) to be presented, confirming Nuwiq®‘s efficacy and safety profile The […]

As part of its ongoing commitment to the global bleeding disorders community, Octapharma is pleased to be a Gold Sponsor of the upcoming World Federation of Haemophilia (WFH) 2022 World Congress, taking place from May 8 to 11, 2022. This continues Octapharma’s long history of involvement and support of the WFH World Congress and the […]

The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management. The development of inhibitors to replacement factor VIII (FVIII) therapy continues to be a significant concern for people with haemophilia […]

Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on July 17–21, 2021. In addition to two Supported Symposia that will discuss the comprehensive management of patients with haemophilia […]